Cleo SG Registers European Patent for In-House Vaccine Development Technology... "Proving Global Technological Excellence"

CreoSG has succeeded in gaining recognition for its vaccine development technology in the global market. On the 22nd, CreoSG announced that it had been granted a patent by the European Patent Office for the core technology of its proprietary universal vaccine development platform, ‘SUV-MAP’.

The patent registered by CreoSG this time pertains to the technology of the ‘modified Vesicular Stomatitis Virus (VSV) matrix protein.’ This technology is one of the three core technologies of the universal vaccine development platform SUV-MAP, enabling safe and effective human expression of VSV through genetic manipulation.

Although the European patent examination process takes considerable time, it is characterized by the ability to register patents simultaneously across multiple countries. Under the European unitary patent system, the approved technology can be patented in a total of 17 countries belonging to the European Union (EU), including France, Germany, and Italy.

SUV-MAP is a vaccine development platform based on CreoSG’s recombinant VSV vector technology. By applying VSV technology, genes can be loaded onto the vector to induce an immune response against target substances, thereby forming an immune system. CreoSG has proven its technological prowess in the global market by acquiring patents for SUV-MAP related core technologies in more than 10 countries.

A representative from CreoSG stated, “We have completed verification of efficacy and safety while developing vaccines through SUV-MAP, and with this new patent registration, our technology has once again been recognized in the global market. SUV-MAP can load target virus genes of various viral pathogens, making it highly applicable for vaccines targeting infectious diseases.”

He added, “In addition to this attenuation technology, we will continue to acquire patents for SUV-MAP core technologies such as virus expression and combination administration, thereby building global entry barriers.”

Based on SUV-MAP, CreoSG is developing various vaccines including for AIDS as well as ▲COVID-19 ▲MERS ▲Zika ▲Crimean-Congo Hemorrhagic Fever ▲Severe Fever with Thrombocytopenia Syndrome (SFTS) ▲Hemorrhagic Fever with Renal Syndrome (HFRS). During the development of vaccines for COVID-19, MERS, and Zika, patents for individual diseases were also obtained.

This content was produced with the assistance of AI translation services.